Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor

Archives of Internal Medicine

Volumn 160, Issue 4, 2000, Pages 437-444

  Fox, D A ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CHIMERIC ANTIBODY; COLLAGENASE; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; GOLD DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LENERCEPT; LYMPHOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; PENICILLAMINE; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; DRUG HALF LIFE; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; T LYMPHOCYTE;

EID: 0034723762     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.4.437     Document Type: Review

References (92)

1. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872.
2. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol. 1998;25(suppl 53): 8-12.
3. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum. 1997;40:598-609.
4. Breedveld FC. New insights in the pathogenesis of rheumatoid arthritis. J Rheumatol. 1998;25 (suppl 53):3-7.
5. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990;33:305-315.
6. Brennan FM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease. Br Med Bull. 1995;51:368-384.
7. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996;26:526-538.
8. Deleuran BW. Cytokines in rheumatoid arthritis: localization in arthritic joint tissue and regulation in vitro. Scand J Rheumatol. 1996;25(suppl 104): 1-34.
9. Starkebaum G. Role of cytokines in rheumatoid arthritis. Sci Med. March/April 1998:6-15.
10. Miossec P. The Th1/Th2 cytokine balance in arthritis. In: Miossec P, van den Berg WB, Firestein GS, eds. T Cells in Arthritis. Basel, Switzerland: Birkhaüser Publisher; 1998:93-109.
11. Old LJ. Tumor necrosis factor (TNF). Science. 1985;230:630-632.
12. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
13. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334:1717-1725.
14. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985;161: 984-995.
15. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987;50:555-563.
16. Tracey KJ, Vlassara H, Cerami A. Cachectin/ tumour necrosis factor. Lancet. 1989;1:1122-1126.
17. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
18. Müller U, Jongeneel CV, Nedospasov SA, Lindahl KF, Steinmetz M. Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex. Nature. 1987;325:265-267.
19. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
20. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/ tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-1227.
21. Starnes HF Jr, Warren RS, Jeevanandam M, et al. Tumor necrosis factor and the acute metabolic response to tissue injury to man. J Clin Invest. 1988; 82:1321-1325.
22. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest. 1986;78:1349-1354.
23. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433-1450.
24. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/ cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986;163:1363-1375.
25. Pober JS, Gimbrone MA Jr. Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986; 137:1893-1896.
26. Leibovich SJ, Poverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature. 1987;329:630-632.
27. Strieter RM, Kunkel SL, Showell HJ, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science. 1989;243:1467-1469.
28. Kehrl JH, Miller A, Fauci AS. Effect of tumor necrosis factor α on mitogen-activated human B cells. J Exp Med. 1987;166:786-791.
29. Ranges GE, Zlotnik A, Expevik T, Dinarello CA, Cerami A, Palladino MA Jr. Tumor necrosis factor α/cachectin is a growth factor for thymocytes. J Exp Med. 1988;167:937-953.
30. Sung S-SJ, Bjorndahl JM, Wang CY, Kao HT, Fu SM. Production of tumor necrosis factor/ cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J Exp Med. 1998;167:937-953.
31. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmunol. 1988;1:363-371.
32. Brennan FM, Maini RN, Feldmann M. TNFα -pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293-298.
33. Neidel J, Schulze M, Lindschau J. Association between degree of bone erosion and synovial fluid levels of tumor necrosis factor a in the knee-joints of patients with rheumatoid arthritis. Inflamm Res. 1995;44:217-221.
34. Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G. Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol. 1996;26:1690-1694.
35. 2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985; 162:2163-2168.
36. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319:516-518.
37. Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage [letter]. Nature. 1986;322:547-549.
38. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258-1265.
39. Leirisalo-Repo M, Paimela L, Jäättelä M, Koskimies S, Repo H. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Scand J Rheumatol. 1995;24:366-371.
40. 125I-labeled human turn or necrosis factor (LuKII) to specific cell surface receptors. J Exp Med. 1985; 162:1099-1104.
41. Tsujimoto M, Yip YK, Vilcek J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci U S A. 1985;82:7626-7630.
42. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature. 1985;318:665-667.
43. Smith CA, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990; 248:1019-1023.
44. Brockhaus M, Schoenfeld H-J, Schlaeger E-J, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87:3127-3131.
45. Thoma B, Grell M, Pfizenmaier K, Scheurich P. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med. 1990; 172:1019-1023.
46. Butler DM, Feldmann M, Di Padova F, Brennan FM. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw. 1994;5:441-448.
47. Seckinger P. Isaaz S, Dayer J-M. A human inhibitor of tumor necrosis factor α. J Exp Med. 1988; 167:1511-1516.
48. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
49. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992;35:1160-1169.
50. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action Scand J Immunol. 1995;42:158-165.
51. Steiner G, Studnicka-Benke A, Witzmann G, Höfler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol. 1995;22:406-412.
52. Roux-Lombard P, Punzi L, Hasler F. et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum. 1993;36: 485-489.
53. Feldmann M, Brennan FM, Williams RO, Elliott MJ, Maini RN. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNFα antibody therapy and its mechanism of action. J Inflamm. 1996;47:90-96.
54. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-664.
55. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
56. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA. 1997;277:1531-1538.
57. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-9788.
58. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol. 1993;151:6602-6607.
59. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244-247.
60. Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A. 1987;84:4273-4277.
61. Barrera P, Boerbooms AMTh, van de Putte LBA, van der Meer JWM. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum. 1996;25:234-253.
62. Barrera P, Boerbooms AMT, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36:1070-1079.
63. Brennan FM, Cope AP, Katsikis P, Gibbons DL, Maini RN, Feldmann M. Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis. In: Andorini L, ed. Selective Immunosuppression: Basic Concepts and Clinical Applications. Basel, Switzerland: S Karger AG; 1995:48-60.
64. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol. 1996;157:3672-3680.
65. Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. In: Kremer JM, ed. Rheumatic Disease Clinics of North America. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1998:593-614.
66. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993;36:1681-1690.
67. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-1127.
68. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
69. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNF-α monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of a double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum. 1996;39(suppl):S123.
70. Maini RN, Breedveld FC, Kalden JR, et al. Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum. 1997;9(suppl):S126.
71. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human antitumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995;34: 334-342.
72. Rankin ECC, Choy EHS, Sopwith AM, Vetterlein O, Panayi GS, Isenberg DA. Repeated doses of 10 mg/kg of an engineered human anti-TNF-α antibody CDP571 in RA patients are safe and effective [abstract]. Arthritis Rheum. 1995;38(suppl): 185.
73. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune "lupus" nephritis. Nature. 1988;331:356-358.
74. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-4031.
75. Camussi G, Lupia E. The future role of antitumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs. 1998;55: 613-620.
76. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine. 1995;7:251-259.
77. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis. In: Kremer JM, ed. Rheumatic Disease Clinics of North America. 3rd ed. Philadelphia, Pa: WB Saunders Co: 1998:579-591.
78. Moreland LW, Margolies G, Heck LW Jr, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996;23:1849-1855.
79. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337: 141-147.
80. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999; 130:478-486.
81. Weinblatt ME, Kremer JM, Bankhurst AD, et al. Phase II/III trial of the TNF receptor p75 Fc fusion protein (TNFR:Fc), Enbrel in combination with methotrexate (MTX) in RA patients. Arthritis Rheum. 1998;41(suppl):S189.
82. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
83. Sander O, den Broeder A, van der Hoogen F, Laan R, van de Putte L, Rau R. 30 Months of treatment with a TNFα receptor-fusion protein (TNFR55-IgG1, RO 45-2081) in patients with severe refractory RA [abstract]. Arthritis Rheum. 1987;40(suppl):S81.
84. Urs C, Ghuerkauf R, Stevens R, Lesslauer W, and the RA and MS study groups. Immunogenicity of a human TNFR55-IgG1 fusion protein (Lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients [abstract]. Arthritis Rheum. 1998;41(suppl):S58.
85. Martin S, Frazier J, Seely J, et al. A genetically modified tumor necrosis factor receptor I (sTNF-RI) that does not elicit antibody response in primates [abstract]. Arthritis Rheum. 1998;41(suppl): S58.
86. Nicod LP, Isler P, Chicheportiche R, Songeon F, Dayer J-M. Production of prostaglandin E2 and collagenase is inhibited by the recombinant soluble tumour necrosis factor receptor p55-human γ3 fusion protein at concentrations a hundred-fold lower than those decreasing T cell activation. Eur Cytokine Netw. 1996;7:757-763.
87. Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med. 1998;128:231-233.
88. Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998;4:78-83.
89. McKall-Faienza KJ, Kawai K, Kündig TM, et al. Absence of TNFRp55 influences virus-induced autoimmunity despite efficient lymphocylic infiltration. Int Immunol. 1998;10:405-412.
90. Kremer JM. Combination therapy with biological agents in rheumatoid arthritis: perils and promise. Arthritis Rheum. 1998;41:1548-1551.
91. Chikanza IC, Jawed S, Naughton D, Blake DR. Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol. 1998;50:357-369.
92. Ettinger R, Mebius R, Browning JL, et al. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. Int Immunol. 1997;10:727-741.